U.S. SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 4
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or
Section 30(f) of the Investment Company Act of 1940
[ ] Check box if no longer subject to Section 16. Form 4 or Form 5 obligations
may continue. See Instruction 1(b).
_______________________________________________________________________________
1. Name and Address of Reporting Person*
Novartis AG
-------------------------------------------------------------------------------
(Last) (First) (Middle)
Schwarzwaldalle 215
-------------------------------------------------------------------------------
(Street)
CH-4002, Basel Switzerland
-------------------------------------------------------------------------------
(City) (State) (Zip)
_______________________________________________________________________________
2. Issuer Name and Ticker or Trading Symbol
Chiron Corporation/CHIR
_______________________________________________________________________________
3. IRS Identification Number of Reporting Person, if an Entity (Voluntary)
_______________________________________________________________________________
4. Statement for Month/Year
10/00
_______________________________________________________________________________
5. If Amendment, Date of Original (Month/Year)
_______________________________________________________________________________
6. Relationship of Reporting Person to Issuer
(Check all applicable)
[ ] Director [x] 10% Owner
[ ] Officer (give title below) [ ] Other (specify below)
_______________________________________________________________________________
7. Individual or Joint/Group Filing (Check applicable line)
[ ] Form filed by one Reporting Person
[x] Form filed by more than one Reporting Person
_______________________________________________________________________________
<PAGE>
===============================================================================
Table I -- Non-Derivative Securities Acquired, Disposed of,
or Beneficially Owned
===============================================================================
<TABLE>
<CAPTION>
6.
4. 5. Owner-
Securities Acquired (A) or Amount of ship
3. Disposed of (D) Securities Form: 7.
Transaction (Instr. 3, 4 and 5) Beneficially Direct Nature of
2. Code ------------------------------- Owned at End (D) or Indirect
1. Transaction (Instr. 8) (A) of Month Indirect Beneficial
Title of Security Date ------------ Amount or Price (Instr. 3 (I) Ownership
(Instr. 3) (mm/dd/yy) Code V (D) and 4) (Instr.4) (Instr. 4)
-----------------------------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C> <C> <C> <C> <C> <C>
Common Stock 10/6/00 C 348,310 A $47 348,310 D
-----------------------------------------------------------------------------------------------------------------------------------
Common Stock 5,121,460 I Through
Novartis
Pharma AG
-----------------------------------------------------------------------------------------------------------------------------------
Common Stock 73,842,852 I Through
Novartis
Biotech
-----------------------------------------------------------------------------------------------------------------------------------
Common Stock 7,456 I Through
Novartis
Corporation
-----------------------------------------------------------------------------------------------------------------------------------
===================================================================================================================================
</TABLE>
Reminder: Report on a separate line for each class of securities beneficially
owned directly or indirectly.
* If the Form is filed by more than one Reporting Person, see Instruction
4(b)(v).
<PAGE>
FORM 4 (continued)
Table II -- Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
===============================================================================
<TABLE>
<CAPTION>
10.
9. Owner-
Number ship
of Form
2. Deriv- of
Conver- 5. 7. ative Deriv- 11.
sion Number of Title and Amount Secur- ative Nature
or Derivative 6. of Underlying 8. ities Secur- of
Exer- 4. Securities Date Securities Price Bene- ity: In-
cise 3. Trans- Acquired (A) Exercisable and (Instr. 3 and 4) of ficially Direct direct
Price Trans- action or Disposed Expiration Date ---------------- Deriv- Owned (D) or Bene-
1. of action Code of(D) (Month/Day/Year) Amount ative at End In- ficial
Title of Deriv- Date (Instr. (Instr. 3, ---------------- or Secur- of direct Owner-
Derivative ative (Month/ 8) 4 and 5) Date Expira- Number ity Month (I) ship
Security Secur- Day/ ------ ------------ Exer- tion of (Instr. (Instr. (Instr. (Instr.
(Instr. 3) ity Year) Code V (A) (D) cisable Date Title Shares 5) 4) 4) 4)
-----------------------------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C> <C> <C> <C> <C> <C> <C> <C> <C> <C> <C>
7-1/4% Con- $47 10/6/00 C $10,069,000 Anytime 7/01/15 Common 348,310 0 D
vertible Sub-
ordinated
Debentures due
2015
-----------------------------------------------------------------------------------------------------------------------------------
===================================================================================================================================
</TABLE>
Explanation of Responses:
On October 6, 2000, Novartis AG converted $10,069,000 fact amount of Chiron
7-1/4% Convertible Subordinated Debentures due 2015 into 348,310 shares of
Chiron common stock. Novartis AG is the beneficial owner of a total of
79,320,078 Common Shares of Chiron Corporation. Of such shares, 5,121,460
shares are owned by Novartis Pharma AG (a wholly owned subsidiary of Novartis
AG) 73,842,852 shares are owned by Novartis Biotech Partnership, Inc. (an
indirect wholly owned subsidiary of Novartis AG) 7,456 shares are owned by
Novartis Corporation (an indirect wholly owned subsidiary of Novartis AG) and
348,310 shares were obtained by the conversion of the 7-1/4% Convertible
Subordinated Debentures.
/s/ Robert L. Thompson, Jr. November 13, 2000
-------------------------------------------- -----------------------
**Signature of Reporting Person Date
** Intentional misstatements or omissions of facts constitute Federal
Criminal Violations.
See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed.
If space provided is insufficient, see Instruction 6 for procedure.
Potential persons who are to respond to the collection of information
contained in this form are not required to respond unless the form displays a
currently valid OMB number.
Page 2
<PAGE>
Additional Reporting Novartis Pharma AG (a wholly owned
Person: subsidiary of Novartis AG)
Address: Schwarzwaldallee 215; CH-4002
Basel, Switzerland
Designated Filer: Novartis AG
Issuer & Ticker Symbol: Chiron Corporation/CHIR
Statement for Month/Year: 10/00
/s/ Wayne P. Merkelson 11/13/00
------------------------- ----------
Signature of Date
Reporting Person
Additional Reporting Novartis Biotech Partnership, Inc. (an
Person: indirect wholly owned subsidiary of
Novartis AG)
Address: 564 Morris Avenue;
Summit, NJ 07901
Designated Filer: Novartis AG
Issuer & Ticker Symbol: Chiron Corporation/CHIR
Statement for Month/Year: 10/00
/s/ Jeff Benjamin 11/13/00
------------------------- ----------
Signature of Date
Reporting Person
Additional Reporting Novartis Corporation (an indirect
Person: wholly owned subsidiary of Novartis
AG)
Address: 564 Morris Avenue;
Summit, NJ 07901
Designated Filer: Novartis AG
Issuer & Ticker Symbol: Chiron Corporation/CHIR
Statement for Month/Year: 10/00
/s/ Wayne P. Merkelson 11/13/00
------------------------- ----------
Signature of Date
Reporting Person
